iBio, Inc. Form 10-Q Summary
Business context and reporting period
iBio is a preclinical biotechnology company using artificial intelligence and machine learning to discover and optimize precision antibodies. The company has transitioned away from its contract development and manufacturing organization (CDMO) operations and is focused on its AI Discovery Platform, immuno-oncology pipeline and an autoimmune PD-1 agonist program.
This filing covers the quarter and six months ended December 31, 2023, the second quarter of fiscal 2024. CDMO results are classified as discontinued operations, and related assets remain held for sale.
Financial performance and position
| Metric | Three months ended December 31, 2023 | Three months ended December 31, 2022 | Six months ended December 31, 2023 | Six months ended December 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $50,000 | $0 |
| R&D expense | $1.5 million | $2.8 million | $3.1 million | $5.3 million |
| G&A expense | $3.0 million | $7.8 million | $6.5 million | $12.9 million |
| Operating loss | $4.5 million | $10.6 million | $9.6 million | $18.2 million |
| Loss from discontinued operations | $3.7 million | $23.0 million | $4.4 million | $33.6 million |
| Net loss | $8.2 million | $33.6 million | $14.0 million | $51.7 million |
| Basic and diluted loss per share | $4.42 | $68.43 | $9.15 | $110.85 |
| Net cash used in operating activities | Not separately provided | Not separately provided | $10.0 million | $21.6 million |
Margins are not meaningful because revenue was zero for the quarter and only $50,000 for the six-month period. Management attributed lower R&D and G&A expenses primarily to performing more work internally, lower consultant and outside-service spending, and reduced personnel costs.
- Cash and cash equivalents were $2.8 million at December 31, 2023.
- Total cash, cash equivalents and restricted cash were $4.1 million, compared with $7.6 million at June 30, 2023.
- Total assets were $34.0 million and stockholders’ equity was $9.2 million at December 31, 2023.
- Accumulated deficit was $302.9 million.
- The company had $12.7 million outstanding under its Woodforest term loan, net of deferred financing costs, at December 31, 2023.
- Other obligations included equipment financing of $323,000, insurance premium financing of approximately $481,000, finance lease obligations of $490,000 and operating lease obligations of $3.3 million.
Material changes versus the prior comparable period
- Quarterly net loss declined to $8.2 million from $33.6 million, primarily because the prior-year period included substantial CDMO asset impairments, inventory reserves and personnel costs.
- Continuing-operations R&D expense decreased 45% for the quarter and 41% for the six-month period.
- Continuing-operations G&A expense decreased 62% for the quarter and 49% for the six-month period.
- Discontinued-operations losses declined substantially, although the company recorded a new $3.1 million impairment of the Bryan, Texas facility during the current quarter.
- The company raised approximately $7.0 million from common-stock sales during the six months, including approximately $4.0 million of net proceeds from the December 2023 public offering and approximately $1.3 million from Lincoln Park sales.
- On November 29, 2023, the company completed a one-for-twenty reverse stock split. Share and per-share information in the filing is presented on a retroactively adjusted basis.
- The December offering included 600,000 common shares, 1.65 million pre-funded warrants and 2.25 million each of Series C and Series D warrants. The pre-funded warrants were exercised, while no common warrants were exercised during the period.
Guidance, outlook, risks and unusual items
Management expects IBIO-101 to progress from IND-enabling work toward an IND filing in calendar 2025, subject to funding availability. The company also expects to continue advancing its TROP-2 x CD3, MUC16, EGFRvIII, CCR8 and autoimmune PD-1 programs, but all are preclinical or discovery-stage programs and no product revenue is expected for several years, if ever.
The company states that its recurring losses, negative operating cash flow and limited liquidity raise substantial doubt about its ability to continue as a going concern. Management’s current plans do not alleviate that doubt for at least 12 months from the filing date. Cash, cash equivalents and restricted cash at December 31, 2023 were not expected to fund operations beyond the third quarter of fiscal 2024 without additional cost reductions, a facility sale, asset monetization, subleasing, collaborations or additional financing. Management indicated operating cash burn was approximately $1.6 million per month.
- The Woodforest term loan matured on March 29, 2024, with approximately $12.7 million outstanding at December 31, 2023. The proposed sale of the Bryan facility was terminated by the buyer in November 2023, and the company did not have a buyer at a price sufficient to repay the loan in full as of the filing.
- The facility was being marketed and auctioned, with management estimating a sale price of approximately $13.8 million less approximately $0.7 million of selling costs. Further impairment could be material if the expected sale price is not achieved.
- On January 16, 2024, the company borrowed approximately $1.0 million in net proceeds under a new Loeb term note. The loan is secured by substantially all company assets other than certain patent-related intellectual property and includes a balloon payment at maturity.
- The company recorded a $3.1 million fixed-asset impairment in discontinued operations during the quarter. It also identified its $5.0 million IBIO-101 indefinite-lived intangible asset as at risk for future impairment, although no impairment was recorded after a valuation estimated fair value at $6.5 million.
- The company has not completed development of or commercialized any therapeutic or vaccine product and expects continued operating losses.
- Management reported that disclosure controls and procedures were effective as of December 31, 2023, with no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether the Woodforest term loan was repaid, refinanced, amended or resulted in a default after its March 29, 2024 maturity date.
- Whether the Bryan facility was sold, at what price, and whether additional impairment or foreclosure-related consequences occurred.
- The company’s post-filing cash balance, monthly cash burn and ability to raise additional capital.
- The dilutive impact of outstanding common and pre-funded warrants, including the 4.5 million Series C and Series D warrants issued in December 2023.
- Progress toward the planned 2025 IBIO-101 IND filing and the funding required to reach that milestone.
- Whether research collaborations generate recurring revenue, milestone payments or only limited upfront license revenue.
- Potential future impairment of IBIO-101 intellectual property and other assets held for sale.